Can a Japanese pharmaceutical become a social innovator?

McKinsey & Company

Insights on Pharmaceuticals & Medical Products Pharmaceuticals Japan DigitalSanten CIO Minori Hara explains how IT is enabling the ophthalmological company to deliver a holistic sense of well-being around eye health.

First-time launchers in the pharmaceutical industry

McKinsey & Company

Insights on Pharmaceuticals & Medical ProductsIncreasingly, small biopharmaceutical companies are launching their new drugs themselves rather than relying on large pharma companies to do it for them. How can they get it right the first time?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Treating COVID-19: A pharmaceutical executive’s view

McKinsey

Cedric Francois, the CEO of pharmaceutical company Apellis, discusses possible approaches to treating COVID-19 patients. Insights on Pharmaceuticals & Medical Products

A ‘GOLD standard’ in brand growth for Japan’s pharmaceutical market

McKinsey

Our GOLD standard will help transform your pharmaceutical brand and achieve accelerated growth. Asia-Pacific

What’s behind the pharmaceutical sector’s M&A push

McKinsey

There are lessons for other industries in the way pharma companies use mergers to innovate, work more efficiently, and bolster product portfolios. Strategy & Corporate Finance Insights

Change in the Japanese pharmaceutical market: Cradle of innovation or grave of corporate profits?

McKinsey

Insights on Pharmaceuticals & Medical ProductsUnderstanding structural shifts in the market can help pharma stakeholders innovate and, ultimately, deliver benefits for patients.

Innovating at the speed of the 21st century in pharmaceuticals

McKinsey

The CEO of Eli Lilly offers perspectives on accelerating change in the industry. Our Insights

Pharma’s digital Rx: Quantum computing in drug research and development

McKinsey & Company

Pharmaceutical companies should reflect on their strategic stance to this promising new technology now. Insights on Pharmaceuticals & Medical Products PharmaceuticalsQuantum computing’s ability to simulate larger, more complex molecules could be game changing.

The race to create a vaccine: A conversation with Frank D’Amelio

McKinsey & Company

The CFO of the pharmaceutical company talks about what it took to develop a COVID-19 vaccine. Strategy & Corporate Finance Insights Pharmaceuticals Strategy & Corporate Finance Strategy

A new operating model for pharma: How the pandemic has influenced priorities

McKinsey & Company

Insights on Life Sciences PharmaceuticalsThe COVID-19 pandemic has prompted pharma companies to rethink their organizational strategies. A survey of executives suggests where value might lie.

Survey 106

How could gene therapy change healthcare in the next ten years?

McKinsey & Company

Insights on Pharmaceuticals & Medical Products PharmaceuticalsCell and gene therapies are at the forefront of innovation and transforming how we treat and potentially cure certain diseases. What will the next decade hold for these life-changing therapies?

Getting to work: Employers’ role in COVID-19 vaccination

McKinsey & Company

Insights on Pharmaceuticals & Medical Products Public health Pharmaceuticals Health care services Healthcare Pharmaceuticals & Medical Products Public and Social SectorsEmployers can consider a set of actions that supports COVID-19-vaccine adoption among employees by building conviction and making vaccination as convenient and “costless” as possible.

Africa needs vaccines. What would it take to make them here?

McKinsey & Company

Insights on Pharmaceuticals & Medical Products Pharmaceuticals Medical products Public & Social Sector AfricaFor decades, private companies, investors, and public-health leaders have taken a pass on domestic vaccine manufacturing.

Roche’s Infinity model: Helping to transform the lives of patients with rare diseases

McKinsey & Company

Anne Nijs explains how the rare-disease group at Roche Pharmaceuticals pioneered a new model that puts the patient experience at the center of healthcare innovation and delivery. Insights on Pharmaceuticals & Medical Products Pharmaceuticals Product development

Embedding ‘smart quality’ culture and capabilities in the organization

McKinsey & Company

Pharmaceutical and medical-device companies can get the most value from “smart quality” processes enabled with new technologies by adopting a holistic approach to building culture and capabilities. Insights on Life Sciences Pharmaceuticals Leadership Strategy

An inflection point for biosimilars

McKinsey & Company

Insights on Pharmaceuticals & Medical Products Biotechnology PharmaceuticalsWith rising US adoption, biosimilars are gathering even more momentum. Successful companies will innovate their commercial models, rethink their portfolio management, and accelerate their R&D.

Moderna’s path to vaccine innovation: A talk with CEO Stéphane Bancel

McKinsey & Company

Insights on Pharmaceuticals & Medical Products Pharmaceuticals Public health Health care services Managing in Uncertainty InnovationModerna’s delivery of a COVID-19 vaccine comes on the heels of revolutionary science that may accelerate innovation across the industry well into the future.

Gene-therapy innovation: Unlocking the promise of viral vectors

McKinsey & Company

Insights on Pharmaceuticals & Medical Products Pharmaceuticals BiotechnologyViral-vector gene therapies show great promise, but the full extent of their clinical impact in the long term is not yet certain. Success depends on innovative solutions that remain under development.

Fulfilling the promise of advanced analytics in oncology

McKinsey & Company

Insights on Pharmaceuticals & Medical Products Pharmaceuticals Oncology/Cancer Analytics Big dataAdvanced analytics will transform cancer care, but companies have been slow to adopt it. Progress requires a strategy that not only builds data and talent but also embraces experimentation.

The Pharmaceutical Industry Needs a Customer-Centric Digital Transformation - SPONSOR CONTENT FROM INDEGENE

Harvard Business

Sponsor content from Indegene. Innovation Customer service Technology Sponsor Content

Digitization, automation, and online testing: Embracing smart quality control

McKinsey & Company

Insights on Pharmaceuticals & Medical Products PharmaceuticalsThe smart quality approach allows pharma companies to digitize, automate, and integrate their quality controls, making them faster, more effective, and more efficient.

Four ways pharma companies can make their supply chains more resilient

McKinsey & Company

Pharmaceutical supply chains have become global and complex. Insights on Life Sciences Pharmaceuticals Supply chain managementWith more outsourcing, new modalities, and novel ways to reach patients, it’s critical to ensure that they can withstand shocks.

Why the Pharmaceutical Industry is Booming in Japan - SPONSOR CONTENT FROM THE GOVERNMENT OF JAPAN

Harvard Business

That rule of life is no secret to pharmaceutical companies across the globe. Japan remains the world’s second-biggest pharmaceuticals market, behind only the United States and China. The biggest change for pharma in Japan was the 2014 revision of the nation’s keystone pharmaceuticals law, renamed the PMD Act—for pharmaceutical and medical devices. Older people need more medicine.

No place like home? Stepping up the decentralization of clinical trials

McKinsey & Company

Insights on Pharmaceuticals & Medical Products PharmaceuticalsThe COVID-19 pandemic has catalyzed the adoption of decentralized clinical trials while highlighting the critical benefits of virtual trials and improving the patient and physician experience.

Sleep on it: Addressing the sleep-loss epidemic through technology

McKinsey & Company

Insights on Pharmaceuticals & Medical Products Medical productsSleep deprivation has become a global problem. Can the burgeoning sleep-tech industry provide solutions?

Moving digital health forward: Lessons on business building

McKinsey & Company

Insights on Pharmaceuticals & Medical ProductsBuilding a successful digital health business involves several strategic steps, as illustrated through the lens of six digital health start-ups.

Clinical supply chains: How to boost excellence and innovation

McKinsey & Company

Insights on Life Sciences Pharmaceuticals Supply chain managementClinical trials have increased in number and have become more complex, decentralized, and patient-centric. While this puts pressure on clinical drug supply, it also brings new opportunities.

Precision medicine in practice: Strategies for rare cancers

McKinsey & Company

Insights on Pharmaceuticals & Medical Products Biotechnology Pharmaceuticals Oncology/CancerThe small number of people with rare diseases raises challenges for the development and launch of all therapies for such conditions, but rare cancers face extra barriers to widespread treatment.

Getting strategic about new-product submissions in the pharma industry

McKinsey & Company

Insights on Life Sciences PharmaceuticalsBy rethinking the approach to regulatory submissions, pharma companies can reduce timelines and increase their chances of successful product approvals.

Healthcare innovation: Building on gains made through the crisis

McKinsey

Insights on Pharmaceuticals & Medical ProductsLeaders should consider the lessons and achievements of the COVID-19 crisis in forging new innovation aspirations—and the mechanisms needed to execute them.

How the medtech industry can capture value from digital health

McKinsey & Company

Insights on Pharmaceuticals & Medical Products Medical productsMedtech companies could play a major role in the digital transformation of healthcare that is under way, but they will have to make some big changes to the way they operate—and fast.

Recalculating the future of drug development with quantum computing

McKinsey

Insights on Pharmaceuticals & Medical ProductsTwo experts discuss how quantum computing can help solve intractable problems in drug discovery and development.

Making quality assurance smart

McKinsey & Company

Pharmaceutical and medtech companies can dramatically improve quality assurance processes by applying a ‘smart quality’ lens and cutting-edge technologies. Insights on Pharmaceuticals & Medical Products

The dawn of China biopharma innovation

McKinsey & Company

Insights on Life Sciences Pharmaceuticals Medical products ChinaChinese biopharma is making a mark on the global stage as the rapidly evolving regulatory landscape and maturing innovation ecosystem spur significant value creation.

Omnichannel engagement in medtech: The time is now

McKinsey & Company

Insights on Pharmaceuticals & Medical Products Health care services Medical products Health care providers

Integrated evidence generation: A paradigm shift in biopharma

McKinsey & Company

Insights on Life Sciences Medical products PharmaceuticalsBiopharma companies should consider a new, integrated approach to evidence-generation strategies to better demonstrate the value of therapies to all stakeholders.

The Bio Revolution: Innovations transforming economies, societies, and our lives

McKinsey

Insights on Pharmaceuticals & Medical ProductsAdvances in biological science could transform economies and societies, helping to tackle global challenges from climate change to pandemics.

Fast-forward: Will the speed of COVID-19 vaccine development reset industry norms?

McKinsey & Company

Insights on Pharmaceuticals & Medical ProductsA review of the funding, operational, technological, and regulatory factors that allowed for fast development of COVID-19 vaccines shows which will remain relevant for future efforts—and which won’t.

The UK biotech sector: The path to global leadership

McKinsey & Company

Insights on Life Sciences Pharmaceuticals Medical products United KingdomThe United Kingdom is Europe’s leading biotech hub in breakthrough life-sciences start-ups. How is this hub maturing relative to its global peers, and what lies ahead on the road to sustainable scale?

Designing an agile transformation in pharma R&D

McKinsey

Pharmaceutical companies are increasingly turning to the concept of agility to help them transform their R&D functions. Insights on Pharmaceuticals & Medical Products

Agile 77